Senseonics Holdings (NYSE-American: SENS) — maker of an implantable continuous glucose monitoring system for people with diabetes — has extended its distribution agreement with Roche Diabetes Care.
The agreement extension, announced yesterday, has Roche continuing as Senseonics’ exclusive distributor in Europe, the Middle East and Africa — excluding Scandinavia and Israel. The agreement also adds 17 countries including Brazil, Russia, India and China where Roche will have exclusive distribution.
Senseonics officials boast that the company’s Eversense device is the first CGM system with an implantable sensor that someone with diabetes can wear for up to 90 days.
The post Senseonics extends distribution agreement with Roche Diabetes Care appeared first on MassDevice.